CN108779123B - 稠合四环化合物、其组合物和用途 - Google Patents

稠合四环化合物、其组合物和用途

Info

Publication number
CN108779123B
CN108779123B CN201780005620.6A CN201780005620A CN108779123B CN 108779123 B CN108779123 B CN 108779123B CN 201780005620 A CN201780005620 A CN 201780005620A CN 108779123 B CN108779123 B CN 108779123B
Authority
CN
China
Prior art keywords
pyrrolo
benzo
bromo
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780005620.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108779123A (zh
Inventor
C·C·马科马斯
M·H·塞拉诺斯-吴
J·P·瓦卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tabomedex Biosciences LLC
Tebo Biotechnology Co ltd
Original Assignee
Tabomedex Biosciences LLC
Tebo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tabomedex Biosciences LLC, Tebo Biotechnology Co ltd filed Critical Tabomedex Biosciences LLC
Publication of CN108779123A publication Critical patent/CN108779123A/zh
Application granted granted Critical
Publication of CN108779123B publication Critical patent/CN108779123B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780005620.6A 2016-01-04 2017-01-04 稠合四环化合物、其组合物和用途 Active CN108779123B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04
PCT/US2017/012092 WO2017120164A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN108779123A CN108779123A (zh) 2018-11-09
CN108779123B true CN108779123B (zh) 2025-08-19

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780005620.6A Active CN108779123B (zh) 2016-01-04 2017-01-04 稠合四环化合物、其组合物和用途

Country Status (8)

Country Link
US (2) US10059718B2 (cg-RX-API-DMAC10.html)
EP (1) EP3400228B1 (cg-RX-API-DMAC10.html)
JP (1) JP7068185B2 (cg-RX-API-DMAC10.html)
CN (1) CN108779123B (cg-RX-API-DMAC10.html)
AU (1) AU2017205320B2 (cg-RX-API-DMAC10.html)
ES (1) ES2915901T3 (cg-RX-API-DMAC10.html)
TW (1) TWI730027B (cg-RX-API-DMAC10.html)
WO (1) WO2017120164A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
BR112023013722A2 (pt) * 2021-01-11 2024-01-30 Tabomedex Biosciences Inc Compostos quadracílicos fundidos, composições e usos dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
TWI239333B (en) 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
US20160066387A1 (en) * 2013-03-22 2016-03-03 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors;Ashwin U. Rao，等;《Bioorganic & Medicinal Chemistry Letters》;20111206;第22卷;第1068-1072页，尤其参见第1070页方案3和4，第1071页表1 *

Also Published As

Publication number Publication date
CN108779123A (zh) 2018-11-09
TWI730027B (zh) 2021-06-11
ES2915901T3 (es) 2022-06-27
US10059718B2 (en) 2018-08-28
AU2017205320B2 (en) 2021-06-24
EP3400228A4 (en) 2019-08-14
US20170190713A1 (en) 2017-07-06
EP3400228A1 (en) 2018-11-14
TW201726681A (zh) 2017-08-01
JP7068185B2 (ja) 2022-05-16
US10562909B2 (en) 2020-02-18
WO2017120164A1 (en) 2017-07-13
JP2019501971A (ja) 2019-01-24
CA3010213A1 (en) 2017-07-13
EP3400228B1 (en) 2022-04-13
AU2017205320A1 (en) 2018-07-05
US20180319809A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
KR102662205B1 (ko) 신규 plk1 분해 유도 화합물
CN114929689B (zh) Bcl-2抑制剂
CN110167560B (zh) 四环素化合物和治疗方法
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
CN103492384B (zh) 作为trk抑制剂的化合物和组合物
AU2011323739B2 (en) CDK inhibitors
US20190315732A1 (en) Modulators of proteolysis and associated methods of use
TWI794232B (zh) 激酶抑制劑及其用途
JPWO2008072655A1 (ja) イミダゾチアゾール誘導体
EP4646197A2 (en) Organic compounds as nlrp3 inhibitors
AU2012357169B2 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
US10562909B2 (en) Fused quadracyclic compounds, compositions and uses thereof
JP2023505485A (ja) Ａｔｍキナーゼ阻害剤及び組成物並びにそれらの使用の方法
JP2009298713A (ja) イミダゾチアゾール誘導体
KR20230157467A (ko) 모세혈관 확장성 운동실조증 돌연변이(atm) 키나아제의 선택적 조절제 및 이의 용도
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK40006173B (en) Fused quadracyclic compounds, compositions and uses thereof
US20140171423A1 (en) Agents for treating pain and uses thereof
WO2025231261A1 (en) Bicyclic and heterocyclic amide compounds
CA3195035A1 (en) Covalent egfr inhibitors and methods of use thereof
EA052066B1 (ru) Конденсированные четырехциклические соединения, их композиции и применение
HK40013373A (zh) 四环素化合物和治疗方法
HK1195067B (en) Cdk inhibitors
HK1195067A (en) Cdk inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Tebo Biotechnology Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: TABOMEDEX BIOSCIENCES, LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006173

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant